NIH SBIR Grants: $285K Phase I, $2M Phase II Non-Dilutive Funding for Biotech, Medical Devices & Digital Health Innovation
Comprehensive 2026-2027 guide to National Institutes of Health SBIR/STTR grants providing up to $2,000,000 in non-dilutive funding for therapeutics, biologics, medical devices, diagnostics, and digital health platforms. Complete application strategies, eligibility requirements, success rates, and funding timelines for Phase I ($285,000) and Phase II ($2,000,000) awards supporting biotech startups across all 50 states. NIH SBIR takes no equity, requires no repayment, and funds transformative biomedical research and development advancing human health through innovative small business solutions bringing discoveries from bench to bedside[web:161][web:179][web:182].
NIH SBIR Biotech Grants by Region and Life Sciences Hub (2026-2027 Funding Available)
Life Sciences Hub:
- • Cambridge biotech NIH SBIR
- • Boston therapeutics grants
- • Kendall Square drug discovery
- • MIT Harvard spinouts funding
- • Worcester medical devices
- • Waltham diagnostics SBIR
- • Lexington digital health
200+ NIH awards annually
Biotech Innovation:
- • SF biotech NIH funding
- • South San Francisco biopharma
- • Palo Alto digital health
- • Stanford medical devices
- • Berkeley therapeutics
- • San Diego life sciences
- • LA precision medicine
180+ NIH awards annually
Health Innovation:
- • NYC biotech NIH SBIR
- • Philadelphia drug development
- • Baltimore NIH proximity
- • Research Triangle NC
- • Pittsburgh medical devices
- • DC digital health grants
- • New Jersey biopharma
150+ NIH awards annually
Growing Life Sciences:
- • Seattle biotech NIH funding
- • Austin digital health SBIR
- • Chicago medical devices
- • Denver precision medicine
- • Houston therapeutics
- • Atlanta life sciences
- • Phoenix health tech
100+ NIH awards annually
🔥 High-Demand NIH SBIR Biotech Keywords 2026-2027:
💊 2026-2027 NIH SBIR Program Highlights
Complete NIH SBIR/STTR Funding Ecosystem for Biotech Startups
The National Institutes of Health SBIR/STTR program, also known as NIH Seed Fund, provides non-dilutive grants for research and development of innovative biomedical technologies addressing unmet medical needs. NIH seeks breakthrough innovations in therapeutics, diagnostics, medical devices, and digital health with strong commercialization potential bringing discoveries from laboratories to patients[web:161][web:179][web:182].
Biotech startups can access Phase I funding (up to $285,000) to prove technical feasibility and clinical relevance over 6-12 months, followed by Phase II awards (up to $2,000,000) for product development, clinical validation, and regulatory pathway execution over 24 months. NIH evaluates proposals on scientific merit, innovation, commercial viability, and potential for improving human health across 27 institutes including NCI (cancer), NHLBI (heart/lung), NIAID (infectious disease), NINDS (neurological), NIDDK (diabetes)[web:161][web:185][web:186].
NIH SBIR and STTR Program Details 2026-2027
Complete breakdown of Phase I, Phase II funding programs with biotech topic areas and application timelines
Phase I Program Overview
Phase I Biotech Objectives:
• Scientific Feasibility: Prove biological mechanism, efficacy, safety at preclinical or early clinical stage
• Clinical Relevance: Demonstrate technology addresses unmet medical need with clear patient benefit
• Regulatory Pathway: Identify FDA approval pathway (510k, PMA, IND) and key regulatory milestones
• IP Protection: File provisional patents protecting innovation before public disclosure
• Market Validation: Engage physicians, KOLs, payers validating clinical need and reimbursement potential
Phase I Success Stories - Biotech
💊 Cambridge Drug Discovery - $285K Phase I
Massachusetts biotech received NIH Phase I for novel small molecule targeting oncology validated through in vivo tumor regression studies. Partnered with 2 academic medical centers for Phase II clinical preparation.
Location: Cambridge MA | Tech: Therapeutics | Phase II: Funded $2M
💊 SF Medical Device - $280K Phase I Grant
California medical device startup obtained NIH SBIR Phase I for minimally invasive surgical tool reducing complications 60% validated through cadaver studies. 510k pathway identified with FDA pre-submission meeting completed.
Location: San Francisco CA | Tech: Medical Device | FDA: 510k pathway
💊 Boston Diagnostics - $285K Phase I Award
Massachusetts diagnostics company secured NIH Phase I for rapid infectious disease test achieving 98% sensitivity/specificity in 15 minutes vs 3-day culture. CLIA waiver pathway with 3 hospital pilot sites committed.
Location: Boston MA | Tech: Diagnostics | Accuracy: 98% sensitivity
💊 Seattle Digital Health - $275K Phase I Funding
Washington digital health platform received NIH SBIR for AI-powered remote patient monitoring reducing hospital readmissions 40% validated through 200-patient retrospective study. De novo FDA pathway with CE mark obtained.
Location: Seattle WA | Tech: Digital Health | Impact: -40% readmissions
📍 NIH SBIR Phase I Application Deadlines 2026-2027
Standard Deadlines:
- • January 5, 2026
- • April 5, 2026
- • September 5, 2026
- • January 5, 2027
Review Timeline:
- • Initial review: 2 months
- • Council review: 4 months
- • Award decision: 6-7 months
- • Project start: Month 8
Fast-Track Option:
- • Direct Phase II possible
- • $50K+ investor commitment
- • Combined $1.15M funding
- • Accelerated timeline
Visit seed.nih.gov for exact submission dates across 27 NIH institutes[web:161][web:185]
Phase II Program Overview
Phase II Biotech Activities:
- • Clinical trials (Phase I/II human studies)
- • FDA regulatory submissions (IND, IDE, 510k)
- • Manufacturing scale-up and GMP validation
- • Reimbursement strategy and health economics
- • Commercial partnerships and licensing deals
Phase II Success Stories
💎 Boston Therapeutics - $2M Phase II + Series A
Massachusetts drug company received $2M NIH Phase II for rare disease therapy completing Phase Ib clinical trial. Subsequently raised $15M Series A from top biotech VCs, advancing to Phase II pivotal trial. FDA orphan drug designation obtained.
Location: Boston MA | Clinical: Phase II | Raise: $15M Series A
💎 SF Medical Device - $1.8M Phase II Award
California medical device startup obtained $1.8M NIH Phase II for cardiac intervention device completing 50-patient first-in-human study. FDA PMA pathway, CE mark approved, launched Europe generating $5M revenue. Acquired by medical device giant for $85M.
Location: San Francisco CA | Exit: $85M acquisition | Revenue: $5M
💎 San Diego Diagnostics - $1.5M Phase II Funding
California diagnostics company secured $1.5M NIH Phase II for cancer liquid biopsy test achieving 95% sensitivity in 500-patient validation study. CLIA lab certified, serving 20 hospitals, pre-IPO stage with $25M revenue run-rate and Medicare reimbursement approved.
Location: San Diego CA | Revenue: $25M ARR | Status: Pre-IPO
Major Institutes:
- • NCI: Cancer therapeutics, diagnostics, immunotherapy
- • NHLBI: Cardiovascular, pulmonary, blood disorders
- • NIAID: Infectious disease, vaccines, immunology
- • NINDS: Neurological disorders, brain health
- • NIDDK: Diabetes, kidney, digestive diseases
Medical Devices:
- • NIBIB: Biomedical imaging, medical devices
- • NICHD: Pediatric devices, maternal health
- • NEI: Vision, ophthalmology devices
- • NIDCD: Hearing, communication devices
- • NIAMS: Orthopedic, musculoskeletal devices
Digital Health:
- • Remote patient monitoring platforms
- • AI-powered diagnostics and decision support
- • Telemedicine and virtual care solutions
- • Wearable sensors and health tracking
- • Electronic health records and data analytics
NIH SBIR Application Success Strategies 2026-2027
Clearly articulate serious health condition, patient population size, current treatment limitations, and how innovation improves outcomes with clinical evidence
Provide in vitro, in vivo, or clinical pilot data proving mechanism of action, efficacy, safety with statistical significance reducing reviewer skepticism
Identify specific FDA pathway (510k, PMA, IND), predicate devices, clinical trial design, endpoints, and timeline to market demonstrating regulatory understanding
Include letters from key opinion leader physicians at academic medical centers expressing clinical need and willingness to participate in studies validating market pull
Technology solving minor inconvenience not serious medical condition. NIH funds innovations addressing significant unmet needs improving patient outcomes survival quality of life
Purely computational or theoretical proposal without experimental validation. Reviewers need proof of concept data showing technology works before funding further development
No FDA pathway identified or unrealistic regulatory assumptions. Must show understanding of device classification, clinical trial requirements, approval timeline specific to technology
Explore Other SBIR Programs
NIH is one of 11 agencies offering SBIR/STTR funding. Explore sector-specific guides:
Common Questions About NIH SBIR Grants
What is the NIH SBIR Phase I funding amount?
NIH SBIR Phase I awards generally range up to $305,480 (with waivers) for a 6-12 month period. This funding supports feasibility studies and proof-of-concept work.
What are 'Specific Aims'?
The 'Specific Aims' page is the most critical part of your application. It is a one-page summary of your project goals, expected outcomes, and impact. If reviewers don't like this page, the rest may not matter.
Does NIH offer a Direct-to-Phase II option?
Yes. If you have already performed Phase I-equivalent work (and have the data to prove it), you can bypass Phase I and apply directly for a Phase II award (up to $2M).
What is the Fast-Track application?
Fast-Track allows you to submit both Phase I and Phase II proposals simultaneously. If approved, Phase II funding is triggered automatically after successful completion of Phase I milestones, eliminating the funding gap.
Who reviews NIH SBIR applications?
Applications are reviewed by Scientific Review Groups (Study Sections) composed of external scientists and industry experts, not NIH staff. They score based on Significance, Innovation, Approach, and Team.
What is the difference between SBIR and STTR for NIH?
SBIR allows the small business to do the majority of the work (67% in Phase I). STTR requires a formal partnership with a non-profit research institution (university/lab) which must perform at least 30% of the work.
Ready to Access NIH SBIR Funding?
Get our complete NIH SBIR application guide or work with biotech specialists for expert proposal support.
📥 Free NIH SBIR Guide
Download comprehensive guide with biotech templates and strategies.
Download Free Guide🎯 Who Qualifies?
- US biotech/medtech small businesses under 500 employees
- Must address an unmet medical need within NIH's mission areas
- PI qualifications: Must demonstrate relevant scientific expertise
- Pre-revenue companies welcome — but preliminary data is critical
- 28 NIH Institutes fund SBIR — match your project to the right one
📅 Key Deadlines & Application Windows
- Standard dates: January 5, April 5, September 5 (every year)
- AIDS-related: January 7, May 7, September 7
- Resubmissions: Same deadlines — can resubmit to next cycle with revisions
- Review timeline: ~5 months from submission to funding decision
📊 How Competitive Is This?
NIH SBIR is the gold standard — and the most competitive:
- Phase I success: ~20% (varies by Institute)
- NCI (cancer): ~18% — most competitive
- NIGMS: ~25% — slightly better odds
- Resubmissions score higher: Revised applications have ~35% success
Critical: Contact the relevant NIH Program Officer BEFORE submitting. They can redirect you to the right Institute and improve your scoring chances.
🏆 Recent Award Examples
- NIH SBIR/STTR FY2025: $1.3B across 1,800+ awards
- Average Phase I: $275,000 for 6-12 months
- Average Phase II: $1.5M for 2 years
- Top disease areas funded: Oncology (24%), neurology (16%), infectious disease (14%), rare diseases (12%)